TABLE 1.
ABPM‐Sc | ABPA | p a | |
---|---|---|---|
n (%) | 30 | 46 | − |
Age at onset of ABPM, y | 59 (43–69) | 67 (51–71) | 0.10 |
Women, n (%) | 20 (67) | 27 (59) | 0.63 |
Asthma, n (%) | 15 (50) | 32 (70) | 0.10 |
Age at onset, years | 27 (9–50) | 32 (12–50) | 0.94 |
Treatment step (1–2/3–5, n [%]) | 10/4 (71/29) | 8/22 (27/73) | 0.008 |
Duration between onset of asthma and ABPA, years | 11 (3–42) | 30 (11–41) | 0.12 |
Laboratory data at diagnosis | |||
Peripheral blood eosinophil counts (/μL) | 655 (381–1162) | 983 (472–1505) | 0.15 |
Serum IgE levels (IU/mL) | 2020 (471–5797) | 1954 (530–4583) | 0.92 |
A. fumigatus‐specific IgE, UA/mL | 0.80 (0.10–3.34) | 11.20 (3.29–30.05) | <0.001 |
A. fumigatus‐specific IgG, mgA/L | NA | 68.5 (28.8–125.8) | |
Positive serological tests | |||
A. fumigatus‐specific IgE, n (%) | 19 (66) b | 45 (98) | <0.001 |
A. fumigatus‐specific precipitin/IgG, n (%) | 7 (30) c | 40 (87) | <0.001 |
S. commune‐specific IgE, n (%) | 11 (92) d | NA | |
S. commune‐specific precipitin/IgG, n (%) | 11 (85) e | NA | |
Pulmonary function test | |||
FVC, %predicted | 94 (86–106) | 99 (82–113) | 0.99 |
FEV1, %predicted | 98 (77–109) | 80 (65–92) | 0.008 |
FEV1/FVC, % | 77 (72–81) | 70 (61–80) | 0.03 |
Thoracic computed tomography findings | |||
Central bronchiectasis, n (%) | 25 (83) | 28 (61) | 0.04 |
Mucus plugs, n (%) | 28 (93) | 40 (87) | 0.47 |
High attenuation mucus, n (%) | 22 (76) | 27 (59) | 0.14 |
Infiltration/GGO, n (%) | 24 (80) | 43 (94) | 0.14 |
Fibrotic/cystic change, n (%) | 0 (0) | 8 (17) | 0.02 |
Note: Values are medians (interquartile range) or the proportion of patients in each study group, if not otherwise specified.
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; ABPM‐Sc, ABPM culture positive for S. commune; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GGO, ground‐glass opacity; Ig, immunoglobulin; NA, not assayed.
Between the two groups.
n = 29.
n = 23.
n = 12.
n = 13.